# A Study of LY3415244 in Participants With Advanced Solid Tumors

> **NCT03752177** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LY3415244

## Key facts

- **NCT ID:** NCT03752177
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-22
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated during dose escalation after a determination was made that the risk:benefit ratio no longer favored continued evaluation.
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752177, "A Study of LY3415244 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03752177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*